Global Placental Stem Cells (PSCS) Market, By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications) – Industry Trends and Forecast to 2030.
Placental Stem Cells (PSCS) Market Analysis and Size
Pluripotent stem cells (PSCs) have opened up new opportunities for the discovery and testing of therapeutic drugs and regenerative cellular therapies, contributing to our understanding of developmental biology. These cells are still not completely understood, despite the fact that PSC research has expanded quickly over the past 30 years, getting closer to therapeutic use. The widely acknowledged fundamental ideas of pluripotent stem cell (PSC) generation, characterisation and culture. Even though research has mostly eliminated the hazards and problems associated with the origination and culture of PSCs, ethical concerns still exist, and the development of induced pluripotent stem cells is helping to address them (iPSCs). Future pluripotent stem cell research and regenerative therapy will undoubtedly be influenced by the question of whether or not iPSCs and PSCs are actually identical.
Data Bridge Market Research analyses that the placental stem cells (PSCS) market which is USD 1 billion in 2022, is expected to reach USD 4.91 billion by 2030, at a CAGR of 22% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Placental Stem Cells (PSCS) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
CBR Systems, Inc (U.S.), Cordlife India (India), Cryo-Cell International, Inc. (U.S.), ESPERITE N.V. (Netherlands), LifeCell International Pvt. Ltd. (India), StemCyte India Therapeutics Pvt. Ltd (India), PerkinElmer Inc (U.S.), Global Cord Blood Corporation (Hong Kong), Smart Cells International Limited (U.K.), Vita 34 (Germany)
|
|
Market Opportunities
|
|
Market Definition
The term "pluripotent stem cells" (PSCs) refers to a class of cells that have the ability to differentiate into the majority. PSCs are useful tools for studying the biology of cells at the molecular level as well as for simulating diseases and the development of new drugs. Differentiated PSCs can be used to evaluate cardiac and hepatic toxicity, two key contributors to the morbidity and mortality linked to pharmaceutical use that generate attrition in the pipeline for developing new drugs.
Placental Stem Cells (PSCS) Market Dynamics
Drivers
- Recent advancements
As stated previously, improvements in approaches for directed differentiation, cell tracking, gene function analysis, and gene correction have been made possible by recent rapid developments in the genetic engineering of hPSCs. The nuclease-based technologies, such as ZFNs, TALENs, and CRISPR/Cas9, promise to simplify and improve genetic modifications in hPSCs and their offspring through their high success rates and ease of design.
• Increasing funding for stem cell research projects
The demand for better and more advanced treatments for auto-immune, neurological and coronary heart disease has increased cell-based research funding and cumulative research efforts. For instance, in June 2021, $6.3 million was granted to the University of Sydney for three initiatives that address adult vision loss, cardiovascular events and expanding access to stem cell interventions. The California Institute for Regenerative Medicine granted Stanford physician-researchers approximately $31 million in the same year to start first-in-human trials of stem treatments for treating stroke, heart failure, and a particular form of brain and spinal cord malignancy. These are some of the elements driving the market's expansion.
Opportunities
- Rising number of product launches
The market is anticipated to be driven by an increase in product releases by major industry participants during the forecast period. For instance, in August 2017, the healthcare services company LifeCell unveiled an enhanced umbilical cord-stem cell collection kit that safeguards neonatal stem cells from environmental deterioration and temperature changes.
Restraints/Challenges
- Rising operating expenses
The growth of the placental stem cells (PSCS) market during the above-mentioned forecast period is projected to be hampered by rising operating expenses and a strict regulatory environment. The largest barrier to market expansion will be social and ethical considerations.
This placental stem cells (PSCS) report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the placental stem cells (PSCS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Placental Stem Cells (PSCS) Market Scope
The placental stem cells (PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Service Type
- Sample Preservation and Storage
- Sample Analysis
- Sample Processing
- Sample Collection and Transportation
Application
- Personalized Banking Applications
- Research Applications
- Disease Treatment Studies
- Life Science Research
- Drug Discovery
- Clinical Applications
- Hematopoietic Disorders
- Autoimmune Disorders
- Other Diseases
Placental Stem Cells (PSCS) Market Regional Analysis/Insights
The placental stem cells (PSCS) market is analyzed and market size insights and trends are provided by country, service type and application as referenced above.
The countries covered in the placental stem cells (PSCS) report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the placental stem cells (PSCS) market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The placental stem cells (PSCS) also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for placental stem cells (PSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the placental stem cells (PSCS) market. The data is available for historic period 2011-2021.
Competitive Landscape and Placental Stem Cells (PSCS) Market Share Analysis
The placental stem cells (PSCS) competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to placental stem cells (PSCS) market.
Some of the major players operating in the placental stem cells (PSCS) are:
- CBR Systems, Inc (U.S.)
- Cordlife India (India)
- Cryo-Cell International, Inc. (U.S.)
- ESPERITE N.V. (Netherlands)
- LifeCell International Pvt. Ltd. (India)
- StemCyte India Therapeutics Pvt. Ltd (India)
- PerkinElmer Inc (U.S.)
- Global Cord Blood Corporation (Hong Kong)
- Smart Cells International Limited (U.K.)
- Vita 34 (Germany)
SKU-